In a patient on antipsychotics taking Ingrezza (valbenazine) 80 mg daily who develops persistent oral‑buccal movements and new‑onset drooling, what is the next step in treatment?

Reduce or Discontinue Ingrezza and Reassess the Underlying Antipsychotic Regimen

The persistent oral-buccal movements with new-onset drooling in a patient on Ingrezza 80 mg daily suggests drug-induced parkinsonism rather than inadequately treated tardive dyskinesia, and the next step is to reduce or discontinue Ingrezza while evaluating the causative antipsychotic medication. 1

Understanding the Clinical Picture

This presentation is concerning for Ingrezza-induced parkinsonism, not treatment failure of tardive dyskinesia. The FDA label explicitly warns that valbenazine (Ingrezza) can cause parkinsonism, with drooling being a specific listed symptom 1. Postmarketing reports describe severe parkinson-like symptoms in patients taking Ingrezza for tardive dyskinesia, with most cases occurring within the first two weeks after starting or increasing the dose, though this can occur at any time 1.

Key Diagnostic Clues:

• Drooling (sialorrhea) is a hallmark of drug-induced parkinsonism, not tardive dyskinesia 2, 1
• Oral-buccal movements can occur in both conditions, but the addition of drooling strongly suggests parkinsonism
• The patient is already on the maximum recommended dose (80 mg daily) of Ingrezza

Immediate Management Algorithm

Step 1: Reduce or Discontinue Ingrezza

Reduce the Ingrezza dose to 40 mg daily or discontinue it entirely 1. The FDA label specifically states to "reduce the dose or discontinue treatment in patients who develop clinically significant parkinson-like signs or symptoms" 1. In postmarketing reports, parkinson-like symptoms resolved following discontinuation of Ingrezza therapy 1.

Step 2: Reassess the Underlying Antipsychotic

While adjusting Ingrezza, critically evaluate the causative antipsychotic medication:

• If the patient is on a typical (first-generation) antipsychotic: Consider switching to an atypical antipsychotic with lower propensity for extrapyramidal symptoms 3
• If already on an atypical antipsychotic: Consider dose reduction if clinically feasible, or switch to one with even lower D2 receptor affinity (e.g., quetiapine, clozapine) 4
• The guideline evidence consistently recommends switching to atypical antipsychotics when tardive dyskinesia occurs 3

Step 3: Monitor for Resolution

After reducing or stopping Ingrezza, monitor for improvement in drooling and parkinsonism over 1-2 weeks 1. If symptoms persist despite Ingrezza discontinuation, the underlying antipsychotic is likely the primary culprit.

Important Considerations

Do NOT Add Anticholinergic Medications

While anticholinergic agents (benztropine, trihexyphenidyl) are used for drug-induced parkinsonism from antipsychotics 3, 5, they can worsen tardive dyskinesia 6. Since this patient has underlying TD, anticholinergics should be avoided. The 2001 AACAP guidelines specifically caution against using benztropine or trihexyphenidyl in elderly patients with movement disorders 7.

Alternative Agents for Parkinsonism

If parkinsonism persists after Ingrezza adjustment and antipsychotic optimization, amantadine may be considered as it treats parkinsonism without worsening TD 2, 6. Amantadine is a non-anticholinergic dopaminergic agent that may be preferred in patients with comorbid drug-induced parkinsonism and TD 6.

Distinguishing TD from Drug-Induced Parkinsonism

The clinical distinction is critical 6:

• Tardive dyskinesia: Involuntary facial movements (lip smacking, tongue protrusion, chewing), appears after ≥3 months of antipsychotic treatment
• Drug-induced parkinsonism: Bradykinesia, rigidity, tremor, drooling, appears within hours to weeks of starting/increasing antipsychotic 2

Long-Term Strategy

Once parkinsonism resolves:

1. If TD symptoms return and require treatment: Restart Ingrezza at a lower dose (40 mg) and titrate cautiously while monitoring for parkinsonism 1
2. Optimize the antipsychotic regimen first: Use the lowest effective dose of the antipsychotic with the best side-effect profile for this patient 4, 5
3. Consider deutetrabenazine as an alternative VMAT2 inhibitor if valbenazine consistently causes parkinsonism, though cross-reactivity is possible 8

Common Pitfall to Avoid

Do not increase the Ingrezza dose thinking the TD is inadequately treated. The new-onset drooling is a red flag for parkinsonism, and increasing the dose will worsen this complication 1. The 2020 APA guidelines recommend treating moderate to severe tardive dyskinesia with VMAT2 inhibitors 5, but this assumes the medication is tolerated—parkinsonism is a clear indication to reduce or stop.